Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study
Clin. Cancer Res 2021 Oct 01;[EPub Ahead of Print], A Loehr, A Patnaik, D Campbell, J Shapiro, AH Bryce, R McDermott, B Sautois, NJ Vogelzang, RM Bambury, E Voog, J Zhang, JM Piulats, A Hussain, CJ Ryan, AS Merseburger, G Daugaard, A Heidenreich, K Fizazi, CS Higano, LE Krieger, C Sternberg, SP Watkins, D Despain, AD Simmons, M Dowson, T Golsorkhi, S Chowdhury, W AbidaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.